Dual monoamine modulation for improved treatment of major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 1, 2003, Pages 78-86

  Tran, Pierre V ^a   Bymaster, Frank P ^a   McNamara, Robert K ^a   Potter, William Z ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN; NORADRENALIN TRANSPORTER; REBOXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE 3 MONOOXYGENASE; VENLAFAXINE;

DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EJACULATION DISORDER; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR DEPRESSION; NEUROMODULATION; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037311073     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200302000-00011     Document Type: Review

References (111)

1. Murray CJL, Lopez AD. The Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge (Mass): Harvard University Press, 1996.
2. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62:26-31.
3. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60:4-9.
4. Rosenbaum JF, Hylan TR Costs of depressive disorders: A review. In: Depressive Disorders, Vol 1, Eds. M. Maj & N. Sartorius. John Wiley & Sons LTD. 1999:401-449.
5. Greenberg PE, Stiglin LE, Finkelstein SN, et al. (1993) Depression: a neglected major illness. J Clin Psychiatry 1993;54:405-418.
6. Gumnick JF, Nemeroff CB. Problems with currently available antidepressants. J Clin Psychiatry 2000;61:5-15.
7. Fawcett, J., Barkin R. L. Efficacy issues with antidepressants. J Clin Psychiatry 1997;58:(Suppl 6) 32-39.
8. Richelson E. Treatment of acute depression. Psychiatr Clin North Am 1993;16:461-478.
9. Thase ME, Entsuah R, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
10. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
11. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines: relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-1132.
12. Physicians' Desk Reference. Montvale, NJ.: Medical Economics; 2002.
13. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310:1433-1438.
14. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta analysis. Depress Anxiety 1997;6:10-18.
15. Culpepper L. Early onset of antidepressant actions: impact on primary care. J Clin Psychiatry 2001;62:4-6.
16. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry 2000;61:712-721.
17. Bingefors K, Isacson D, von Knorring, L, et al. Antidepressant-treated patients in an ambulatory care mortality during a nine-year period after first treatment. Br J Psychiatry 1996;169:657-654.
18. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988;153:752-757.
19. Lehmann H, Fenton F, Deutsch M, et al. An 11-year follow-up study of 110 patients. Acta Psychiatr Scand 1988;78:57-65.
20. Segman RH, Shapira B, Gorfine M, et al. Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy. Psychopharmacology (Berl) 1995;19:440-448.
21. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG. et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880.
22. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58.
23. Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993;15:216-243.
24. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59:11-14.
25. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61:4-6.
26. Goodwin FK, Bunney WE. Depressions following reserpine: a reevaluation. Semin Psychiatry 1971;3:435-448.
27. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418.
28. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396.
29. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant actions. Biol Psychiatry 1999;46:212-220.
30. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128.
31. Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity or noradrenaline and serotonin neurons. Eur J Neurosci 2001;13:2077-2087.
32. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
33. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000;61:31-38.
34. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
35. Gjerris A. Do concentrations of neurotransmitters in lumbar CSF reflect cerebral dysfunction in depression? Acta Psychiatr Scand Suppl 1988;345:21-24.
36. Healy D, Leonard BE. Monoamine transport in depression: kinetics and dynamics. J Affect Disord 1987;12:91-103.
37. Garvey MJ, Tuason VB. Urinary levels of 3-methoxy-4-hydroxyphenylglycol predict symptom severity in selected patients with unipolar depression. Psychiatry Res, 1996;62:171-177.
38. Raucoules D, Levy C, Azorin JM, et al. Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study. Encephale 1992;18:611-616.
39. Yates M, Leake A, Candy JM, et al. 5HT2 receptor changes in major depression. Biol Psychiatry 1990;27:489-496.
40. Hrdina PD, Bakish D, Chudzik J. et al. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiatry Neuroscience 1995;20:11-19.
41. Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gent promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000;57:729-738.
42. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994 40:288-295.
43. Anand A, Charney D. Norepinephrine dysfunction in depression. J Clin Psychiatry, 2000;61:16-24.
44. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry, 2000;61:7-11.
45. Anderson IM. SSRIs versus tricyclic antidepressants in depressed in patients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7 (Supp 1):11-17.
46. Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr Scand (Suppl) 2000;402:28-36.
47. Nelson JC, Mazure CM, Bowers MB. Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307.
48. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449.
49. Seth R,Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565.
50. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 2001;178:129-144.
51. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11:9-14.
52. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57:19-25.
53. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants - potential for greater efficacy orjust hype? In: Prog Drug Research, (Ed. E. Jucker) Vol 58, 2002;169-222.
54. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001;26:S3-10.
55. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10:25-35.
56. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62:358-361.
57. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
58. Puzantian T. Mirtazapine, an antidepressant. Am J Health Syst Pharm 1998;55:44-49.
59. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420.
60. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-188.
61. Guelfi JD, Ansseau M, Timmerman L. et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21:425-431.
62. Montgomery SA. Safety of mirtazepine: a review. Int Clin Psychopharmacol 1995;10:37-45.
63. Macher JP, Sichel JP, Serre C, et al. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77-82.
64. Lecrubier Y, Pletan Y, Solles A., et al. Clinical efficacy of milnaplacebo-controlled trials. Int Clin Psychopharmacol 1996;11:29-33.
65. Peuch A, Montgomery SA, Prost JF, et al. Milnacipran, a new sorotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
66. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and norepinephrine reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-151.
67. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998;13:121-128.
68. Serre C, Clerc G, Escande M, et al. An early clinical trial of midalcipran, 1 phenyl-1-diethyl aminocarbonyl-2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. Curr Ther Res 1986;39:156-164.
69. Montgomery SA, Prost JF, Solles A. et al. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996;11:47-51.
70. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.
71. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994;51;3033-3046.
72. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanism of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509.
73. Goldberg HL, Finnerty R. An open-label, variable-dose study of W-Y-45,030 (venlafaxine) in depressed outpatients. Psychopharmacol Bull 1988;24:198-199.
74. Schweizer E, Clary C, Weise C, et al. An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacol Bull 1988;24:195-197.
75. Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-236.
76. Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of sever depression. Depress Anxiety 2000;12 (Suppl 1):50-54.
77. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000;12:55-62.
78. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol, 1995;10:21-27.
79. Benkert O, Gründer G, Wetzel H. et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatry Res 1996;30:441-451.
80. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
81. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998;20:517-526.
82. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 1998;18:19-25.
83. Kent J. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-918.
84. Pitsikas N. Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs 2000;1:116-121.
85. Wong DT. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Invest Drugs 1998;7:1-9.
86. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and noradrenaline uptake. Neuropsychopharmacology 1993;8:23-33.
87. Turcotte JE, Debonnel G, de Montigny, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001;24:511-521.
88. Chalon S, Bieck PR, Goldstein DJ, et al. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition. Neuropsychopharmacolgy 2002;26:698-701.
89. Chalon S, Granier L-A, Vandenhende F. Duloxetine: clinical evidence of sertoninergic and noradrenergic reuptake blockade. Presented at the American College of Neuropsychopharmacology, San Juan, PR. 2000.
90. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231.
91. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Br J Psychiatry (in press).
92. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315.
93. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once-daily dosing versus placebo in the acute treatment of major depression. J Psychiatric Res 2002 (in press).
94. Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001;62:18-21.
95. Baron BM, Ogden A-M, Siegal BW, et al. Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-134.
96. Brunello N, Barbaccia ML, Chuang D-M, et al. Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: Permissive role of serotonergic axons. Neuropharmacology 1982;21:1145-1149.
97. Stockmeier CA, Martine AM, Kellar KJ. A strong influence of serotonin axons on β-adrenergic receptors in rat brain. Science 1985;230: 323-325.
98. Vetulani J, Stawarz RJ, Dingell JV, et al. A possible common mechanism of action of antidepressant treatments. Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedebergs Arch Pharmacol 1976; 293:109-114.
99. Duman RS, Nibuya M, Vaidya VA. A role for CREB in antidepressant action. In: Antidepressants. New Pharmacological strategies (ed Skolnick P), New Jersey: Humana Press. 1997;173-194.
100. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547.
101. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372.
102. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci 2000;20:9104-9110.
103. George MS, Ketter TA, Post RM. Prefrontal cortex dysfunction in clinical depression. Depression 1994;2:59-72.
104. Mayberg HS, Lewis PJ, Regenold W, et al. Paralimibic hypoperfusion in unipolar depression. J Nucl Med 1994;35:929-934.
105. Baxter Jr, LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry, 1989;46:243-250.
106. Rajkowska G, Miguel-Hildalgo, JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry, 1999;45:1085-1098.
107. Rubin E, Sackeim HA, Prohovnik I. et al. Regional cerebral blood flow in mood disorders: IV. Comparison of mania and depression. Psychiatry Res 1995;61:1-10.
108. Sapolsky R. Why stress is bad for your brain. Science 1996;273: 749-750.
109. Sheline Y, Wany P. Gado M. et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996;93:3908-3913.
110. Watanbe Y, Gould E, McEwen B. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992;588:341-345.
111. Stein-Behrens B, Mattson MP, Chang I. et al. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci 1994;14:5373-5380.